Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Brexit Vote Dismays UK Pharma, Triggers Calls To Leverage NHS As Offset

Executive Summary

The UK now urgently needs to leverage the uniqueness of its National Health System to attract global pharma companies and offset the anti-business message contained in Thursday's Brexit vote, and the government's imminent accelerated access review needs to contain the first elements of that objective, according to the Association of the British Pharmaceutical Industry.

You may also be interested in...

Roche Rejoins ABPI After Long Absence To Help Forum Address Brexit

Roche's decision to return to the UK industry body the ABPI reflects the Swiss company’s considerable commercial interests in Britain and the need for drug makers operating there to work more closely together as the Brexit process begins.

Progress Report: EAMS A Limited Success But Could Do Better

The UK's Early Access to Medicines Scheme (EAMS) has been operational for two years, along with a "promising innovative medicine" (PIM) designation, to give patients timely access to new drugs for serious diseases before they are approved. The system has now been independently reviewed and Scrip talks to those in the industry that have first-hand experience of the process.

UK Government Drug Price Revamp Move Surprises The ABPI

Less than two years after the first-ever cap on UK National Health Service drug prices was agreed, the country's Department of Health has announced it wants to change a central part of the pact on grounds it does not provide the NHS with adequate savings or price transparency.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts